journal: NeuroImmune Pharmacology and Therapeutics

Open Access Published since May 20, 2022

NeuroImmune Pharmacology and Therapeutics

ISSN: 2750-6665

Editor-in-chief: Howard E. Gendelman

About this journal

Objective

NeuroImmune Pharmacology and Therapeutics is the official peer-reviewed journal of the Society on NeuroImmune Pharmacology. Owned by the Society, the open-access journal showcases cutting-edge research in four core areas: neuroscience, immunology, pharmacology, and therapeutics. Published manuscripts focus on any one of these subject areas and/or their intersections to advance basic, clinical, and translational science.

Specific aims:

To promote diverse neuroimmune research activities in molecular, biochemical, genetic, and pathogenetic studies that advance pharmacologic and therapeutic scholarship.

To present cutting-edge laboratory, translational, and clinical research on substance use disorders (biology, pathophysiology, behavior, and structure-function relationships) and neurodegenerative, neuroinfectious, metabolic, inflammatory, behavioral, and infectious diseases.

To present therapeutic works with molecular, structural-surgical (interventions), and biochemical approaches that serve to ameliorate, delay, or arrest disease onset and/or progression.

To present new, highly interactive, and cross-disciplinary research that intersects the fields of drug delivery, neuroscience, and immunology relevant to modulating or transforming the neuroimmune axis.

To provide a platform for divergent and prospective points of view, letters, and/or brief communications on recent topics of immediate interest.

To foster immediate/relevant information exchanges for neuroimmune therapeutics, disease prevention and treatment strategies in support of topical supplementary reviews with interactions and/or support of the views and directions of the Society on Neuroimmune Pharmacology.

To support and encourage scientific exchange between Society members, authors in or outside the field of neuroimmune therapeutics, and reaching into an international field of investigators that span the globe.

To promote scholarly submissions on the etiology, prevention, and treatment of neuroimmune disorders (including clinical trials) where therapeutic intervention has proven viable and active.

To define the neuroimmunomodulator properties of neuroimmune innervations and regeneration, and of endogenous and exogenous neuroimmunomodulator substances, that would include (but are not limited to) hormones, neuropeptides, neurotransmitters, cytokines, chemokines, and abused substances.

To advance actively developing fields of research in neuroimmune pharmacology (including but not limited to nano-medicine, therapeutics, technology, and gene editing).

To promote translational research in general and, in particular, a better understanding of the role played by neuroinfectious diseases, inflammation, and stress in disorders of the neuroimmune axis.

The overarching scope of the journal is to provide a platform for promoting the Society’s research and to extend that vision on a global scale in basic, clinical, and translational science.

Supplementary Materials

Topics

External Links

Online Submission of Manuscripts

No ranking information is available for this journal.

Submit

Submission
You can easily submit your manuscript online. Simply go to http://mc.manuscriptcentral.com/nipt and you will be guided through the whole submission and publishing process.

Additionally, the Template for Ethical and Legal Declarations needs to be customized by the submitting author on behalf of all others and uploaded as a separate doc-file at the time of the original submission. Instructions on how to make declarations can be found here.

Your benefits of publishing with us

Open Access publication
Research freely available for all to read and download
Authors retain copyright – articles published under the Creative Commons Attribution (CC-BY-4.0) License
Rapid publication times
Free publication of color figures
Every article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing services
Professional sales and marketing activities

Submission process

Submission of your manuscript via our submission management tool following the Information for Authors
Single-blind peer review process
A decision on your paper is aspired within 4-5 weeks
Accepted articles are published online approx. 3 weeks after acceptance

Please note

Publication language is English. Manuscripts must be written in clear and concise English
The Template for Ethical and Legal Declarations are required for submission
If you have any general questions please visit our FAQ for authors
For more detailed information please contact the NIPT Editorial Office nipt@unmc.edu

We looking forward to receiving your manuscript!

Editorial

Editor-in-Chief
Howard E. Gendelman, M.D.
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, NE, USA

Managing Editor
Doug Meigs, B.A.
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, NE, USA
Contact: nipt@unmc.edu

Editorial Board

Senior Editor (North America)
Kalipada Pahan, Ph.D.
Department of Neurological Sciences
Rush University Medical Center
Chicago, IL, USA

Senior Editor (Asia and Pacific Rim)
Raymond Chuen-Chung Chang, Ph.D.
School of Biomedical Sciences
The University of Hong Kong
Hong Kong, China

Senior Editor (Europe)
Marco Cosentino, M.D., Ph.D.
Department of Medicine and Surgery
University of Insubria
Varese, Lombardy, Italy

Section Editor (Neuroactive and Abused Substances)
Sabita Roy, Ph.D.
Departments of Surgery, Microbiology and Immunology, and Biochemistry
University of Miami Miller School of Medicine
Miami, FL, USA

Section Editor (Imaging and Biomarkers)
Linda Chang, M.D., M.S.
Departments of Diagnostic Radiology and Nuclear Medicine, and Neurology
University of Maryland School of Medicine
Department of Neurology, Johns Hopkins School of Medicine
Baltimore, MD, USA

Section Editor (Neurotherapeutics)
Harris A. Gelbard, M.D., Ph.D.
Department of Neurology
University of Rochester Medical Center
Rochester, NY, USA

Section Editor (Neurodegenerative Disorders)
Tsuneya Ikezu, M.D., Ph.D.
Department of Neuroscience
Mayo Clinic Florida
Jacksonville, FL, USA

Section Editor (Neuroimmunology)
Steven Jacobson, Ph.D.
Viral Immunology Section
National Institute of Neurological Disorders and Stroke
Bethesda, MD, USA

Section Editor (Nanomedicine)
Ram I. Mahato, Ph.D.
Department of Pharmaceutical Sciences
University of Nebraska Medical Center
Omaha, NE, USA

Section Editor (Cell Signaling and Immunity)
Thomas J. Rogers, Ph.D.
Center for Inflammation and Lung Research
Lewis Katz School of Medicine of Temple University
Philadelphia, PA, USA

Section Editor (Immunopharmacology)
Eliseo Eugenin, M.D., Ph.D.
Department of Neuroscience
University of Texas Medical Branch
Austin, TX, USA

Section Editor (Inflammatory Transformation)
Stanley H. Appel, M.D.
Houston Methodist Neurological Institute
Houston Methodist
Houston, TX, USA

Section Editor (Medicinal Chemistry)
Corey R. Hopkins, Ph.D.
Pharmaceutical Sciences
University of Nebraska Medical Center
Omaha, NE, USA

Section Editor (Material Science and Drug Delivery)
Dan Peer, Ph.D.
Laboratory of Precision NanoMedicine
Tel Aviv University
Tel Aviv, Israel

Section Editor (Infectious Disease)
Vicente Soriano, M.D., Ph.D.
Health Sciences School and Medical Center
International University of La Rioja
Madrid, Spain

Advisory Board

Sulie L. Chang, Ph.D. ^*Institute of NeuroImmune Pharmacology and Department of Biological Sciences
Seton Hall University
South Orange, NJ, USA

Santosh Kumar, Ph.D. ^*Department of Pharmaceutical Sciences
College of Pharmacy
University of Tennessee Health Science Center Memphis
Memphis, TN, USA

Jean M. Bidlack, Ph.D. ^*Department of Pharmacology and Physiology
University of Rochester Medical Center
Rochester, NY, USA

Sanjay B. Maggirwar, Ph.D., M.B.A. ^*Department of Microbiology, Immunology, and Tropical Medicine
The George Washington University
Washington, D.C., USA

Carol J. Swarts, M.D. ^**University of Nebraska Medical Center
Seattle, WA, USA

Robert M. Eisenberg, J.D., M.A. ^**
Omaha, NE, USA

* Members of the Journal Publishing Committee of the Society on NeuroImmune Pharmacology.
** Major philanthropic supporters of the journal, NeuroImmune Pharmacology and Therapeutics.

(Deutsch)

Type: Journal
Language: English
Publisher: De Gruyter
First published: May 20, 2022
Publication Frequency: 4 Issues per Year